Dry age-related macular degeneration (AMD) cannot be fully reversed as it is a progressive disease. However, the MacuMira Vision Therapy offers a new and innovative treatment that has shown promising results in restoring some vision for patients with dry AMD. In clinical trials, patients experienced improved vision, which was maintained throughout the duration of the trial. The therapy works by stimulating the retinal pigment epithelium (RPE) cells in the eye to help clear waste products that accumulate in the retina, potentially improving eyesight even in advanced stages of the disease.